By Samantha Black, PhD, The Science Advisory Board editor in chief
Cytiva and Pall, both Danaher companies, will make major investments in manufacturing capacity and services at 13 sites around the globe supporting life science customers, totaling $1.5 billion over two years.
The investments include new sites in the U.S. and U.K., and expansion of existing facilities. The announcement follows five strategic acquisitions made by the companies in 2021 (Vanrx, Austar, GoSilico, Precision NanoSystems, and Intermountain Life Sciences) and is in addition to Cytiva's continuing capacity investments, which are estimated to be $500 million.
Specifically, the companies are investing the following:
- $600 million in chromatography resins (media for analyzing or purifying biomolecules), including the establishment of a new manufacturing site in the U.S.
- $400 million in cell culture media (liquid or powder forms used to grow and cultivate cells prior to purification), with plans to expand operations in the U.S., U.K., and Austria
- $300 million in single-use technologies (bioreactor bags for growing cells and syringe filters for scientific research), with plans to expand operations in the U.S. and U.K., as well as fitting out a new facility in Cardiff, Wales
- $200 million to expand Cytiva and Pall sites across China, the rest of the Asia-Pacific region, Europe, and the U.S.
The companies plan to hire 2,000 people over the next two years at the various facilities.
The investments also address key challenges highlighted in the Global Biopharma Resilience Index, including hiring and training talent, R&D collaboration, supply chain resilience, and manufacturing models.
Copyright © 2021 scienceboard.net